GlobeNewswire Inc.··Erasca, Inc.Erasca Partners with Merck to Advance RAS Cancer Treatment Combination
Erasca partners with Merck to test RAS-targeting drug ERAS-0015 with KEYTRUDA in cancer trials, with Merck supplying pembrolizumab cost-free.
MRKERASoncologyKeytruda